We therefore surmised that inhibition of NF-κB, via stabilization of IκBα was responsible for cytotoxicity and demonstrated that inhibition of NEDDylation may provide a therapeutic option for the treatment of NF-κB-dependent PEL. The gene discussed is NFKB1; the disease is primary effusion lymphoma.